Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2020 filed with the SEC

September 16, 2020August 16, 2022 Alterity Therapeutics

XBRL 30 June 2020 filed with the SEC

2020

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.

Related Posts

Prana’s PBT2 Reverses Memory Loss in Normal Aging

November 27, 2013August 16, 2022

Prana Alzheimer’s disease Development Plan Update

July 17, 2014August 16, 2022

Prana to Present at Cowen & Company Health Care Conference on March 4th in Boston, MA

July 17, 2013August 16, 2022

Recent Posts

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065